Olfactory Neuroblastomas: What Actually Happens in the Long-Term?
Hyams
Kadish
endoscopic surgery
esthesioneuroblastoma
olfactory neuroblastoma
recurrence
survival
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
20 Apr 2022
20 Apr 2022
Historique:
received:
12
03
2022
revised:
15
04
2022
accepted:
18
04
2022
entrez:
14
5
2022
pubmed:
15
5
2022
medline:
15
5
2022
Statut:
epublish
Résumé
The aim of this study was to investigate the long-term oncologic outcome and review the state of the art in the management of olfactory neuroblastomas. The records of all patients treated for olfactory neuroblastomas in two academic departments between 1975 and 2012 were evaluated retrospectively. Data on epidemiological parameters were collected (age, gender), along with staging (Kadish, Morita), histologic grading (Hyams), time and form of treatment, locoregional control, and disease-specific and overall survival. Patients with other malignant diseases, distant metastases of olfactory neuroblastomas at the time of initial diagnosis, a follow-up time of less than 5 years, or insufficient clinical-pathological data were excluded from further analysis. In total, 53 cases made up our final study sample (26 men, 27 women; male-female ratio 0.96:1). Their mean age was 48.6 years (range: 10-84 years). The mean follow-up time was 137.5 months (4-336 months, SD: 85.0). A total of 5 out of 53 study cases (9.4%) showed metastatic involvement of the neck at the time of initial presentation. Local recurrence was detected in 8/53 (15.1%) and regional recurrence in 7/53 of our study cases (13.2%). Three patients (42.8%) from the group of cases with surgery as the sole form of management (7/53, 13.2%) died due to the disease. The cumulative disease-specific survival and overall survivalfor the whole group of patients were 88.6% and 63.6%, respectively. The cumulative disease-specific survival stratified by Kadish A/B vs. Kadish C/D as well as Hyams I/II vs. Hyams III/IV showed superior results for limited tumors, albeit without significance, and low-grade tumors (highly significant difference). Craniofacial or sometimes solely endoscopically controlled resection can warrant resection of the olfactory neuroblastoma with wide margins. However, locoregional failures and distant metastases can occur after a long period of time. The non-negligible incidence of regional recurrences, partly in unusual localizations, leads us to consider the need to identify the "recurrence-friendly" cases and to perform individualized elective irradiation of the neck in cases with high-risk features.
Identifiants
pubmed: 35566413
pii: jcm11092288
doi: 10.3390/jcm11092288
pmc: PMC9105484
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Int J Radiat Oncol Biol Phys. 1993 Nov 15;27(4):835-42
pubmed: 8244813
J Clin Neurosci. 2016 Feb;24:99-104
pubmed: 26563603
Radiat Oncol. 2020 Sep 18;15(1):219
pubmed: 32948223
Arch Otolaryngol Head Neck Surg. 1994 Jul;120(7):699-702
pubmed: 8018319
Skull Base. 2008 Sep;18(5):327-37
pubmed: 19240832
Laryngoscope. 2014 Jul;124(7):1542-9
pubmed: 24347437
Laryngoscope. 1992 Aug;102(8):843-9
pubmed: 1495347
Laryngoscope. 2003 Mar;113(3):502-7
pubmed: 12616204
Head Neck. 2021 Apr;43(4):1097-1104
pubmed: 33301222
Radiat Oncol. 2011 Apr 25;6:41
pubmed: 21518449
J Laryngol Otol. 1998 Jul;112(7):628-33
pubmed: 9775291
Cancers (Basel). 2018 Nov 20;10(11):
pubmed: 30463343
AJNR Am J Neuroradiol. 2008 Sep;29(8):1561-3
pubmed: 18499797
Radiother Oncol. 2015 Nov;117(2):328-32
pubmed: 26558687
Am J Rhinol. 2001 Jul-Aug;15(4):271-9
pubmed: 11554661
Am J Rhinol Allergy. 2021 Jul;35(4):525-534
pubmed: 33174762
Bull Cancer. 2020 Sep;107(9):934-945
pubmed: 32896369
Head Neck. 2005 Feb;27(2):138-49
pubmed: 15654688
Head Neck. 2019 Jun;41(6):1738-1744
pubmed: 30620443
Neurosurgery. 1993 May;32(5):706-14; discussion 714-5
pubmed: 8492845
Top Magn Reson Imaging. 2021 Jun 1;30(3):151-158
pubmed: 34096898
Pract Radiat Oncol. 2016 Jul-Aug;6(4):241-247
pubmed: 26979544
Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e255-61
pubmed: 21676553
Laryngoscope. 2003 Nov;113(11):1935-8
pubmed: 14603051
Eur Arch Otorhinolaryngol. 2010 Nov;267(11):1667-71
pubmed: 20706843
Eur Arch Otorhinolaryngol. 2006 Aug;263(8):778-82
pubmed: 16691416
Neurosurg Rev. 2011 Oct;34(4):465-75
pubmed: 21655908
Laryngoscope. 1990 Nov;100(11):1199-201
pubmed: 2233084
Cancer. 1994 May 15;73(10):2556-62
pubmed: 8174053
J Neurooncol. 2008 Nov;90(2):201-4
pubmed: 18633576
Laryngoscope. 2016 Jul;126(7):1556-61
pubmed: 26865537
Laryngoscope. 2016 Jun;126(6):1373-9
pubmed: 26607219
Otolaryngol Head Neck Surg. 2004 May;130(5):567-74
pubmed: 15138422
Cancer Manag Res. 2018 May 29;10:1359-1364
pubmed: 29881306
Head Neck. 2014 Apr;36(4):524-30
pubmed: 23780581
Cancer. 1976 Mar;37(3):1571-6
pubmed: 1260676
Laryngorhinootologie. 2006 Oct;85(10):723-30
pubmed: 16673299
Otolaryngol Head Neck Surg. 2008 Apr;138(4):452-8
pubmed: 18359353